Literature DB >> 12032890

Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach.

David L Paterson.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12032890     DOI： 10.1086/340532

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  19 in total

1.  Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.

Authors:  Jesús Rodríguez-Baño; Maria Dolores Navarro; Luisa Romero; Luis Martínez-Martínez; Miguel A Muniain; Evelio J Perea; Ramón Pérez-Cano; Alvaro Pascual
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients.

Authors:  Kenneth M Wener; Vered Schechner; Howard S Gold; Sharon B Wright; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

3.  Acquisition of imipenem-resistant Acinetobacter baumannii in a pediatric intensive care unit: A case-control study.

Authors:  Aspasia Katragkou; Maria Kotsiou; Charalampos Antachopoulos; Alexis Benos; Danai Sofianou; Maria Tamiolaki; Emmanuel Roilides
Journal:  Intensive Care Med       Date:  2006-06-21       Impact factor: 17.440

4.  Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.

Authors:  C Routsi; M Pratikaki; E Platsouka; C Sotiropoulou; S Nanas; V Markaki; C Vrettou; O Paniara; H Giamarellou; C Roussos
Journal:  Infection       Date:  2010-03-12       Impact factor: 3.553

5.  Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase.

Authors:  Simone Aranha Nouér; Marcio Nucci; Márcia P de-Oliveira; Flávia Lúcia Piffano Costa Pellegrino; Beatriz Meurer Moreira
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains.

Authors:  Jung-Jr Ye; Ching-Tai Huang; Shian-Sen Shie; Po-Yen Huang; Lin-Hui Su; Cheng-Hsun Chiu; Hsieh-Shong Leu; Ping-Cherng Chiang
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

7.  Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance.

Authors:  Ebbing Lautenbach; Joshua P Metlay; Mark G Weiner; Warren B Bilker; Pam Tolomeo; Xiangqun Mao; Irving Nachamkin; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-01       Impact factor: 3.254

8.  Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients.

Authors:  Christina Routsi; Maria Pratikaki; Evangelia Platsouka; Christina Sotiropoulou; Vasileios Papas; Theodoros Pitsiolis; Athanassios Tsakris; Serafeim Nanas; Charis Roussos
Journal:  Intensive Care Med       Date:  2013-04-20       Impact factor: 17.440

9.  Colonization and persistence of antibiotic-resistant Enterobacteriaceae strains in infants nursed in two neonatal intensive care units in East London, United Kingdom.

Authors:  Michael Millar; Alex Philpott; Mark Wilks; Angela Whiley; Simon Warwick; Enid Hennessy; Pietro Coen; Stephen Kempley; Fiona Stacey; Kate Costeloe
Journal:  J Clin Microbiol       Date:  2007-11-26       Impact factor: 5.948

10.  Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex.

Authors:  Teena Chopra; Dror Marchaim; Paul C Johnson; Reda A Awali; Hardik Doshi; Indu Chalana; Naomi Davis; Jing J Zhao; Jason M Pogue; Sapna Parmar; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.